Trans-Hit Bio (THB) has announced the signing of an exclusive partnership with Professor Hugo A. Barrera-Saldaña. THB now has collaborations with Mexican institutions such as ONCARE, LABOPAT and National Nutrition Institute (INCMNSZ), and Prof. Barrera-Saldaña’s company Vitagénesis.
Trans-Hit Biomarkers Inc is the worldwide biospecimen access CRO, founded in 2009, headquartered in Montréal, Québec, Canada, with a most extensive collection capability for biospecimens and clinical samples through an unrivalled worldwide partnered-network of state-of-the-art biorepositories.
The company, led by a team of scientists with a solid background in biomedical research, advises and provides Industry with the best solutions to help design and conduct studies in various fields including oncology, infectiology, and CNS diseases. Continuous support is provided throughout the entire process from initial request to the moment the samples are delivered, and beyond.
Vitagénesis is a pioneer of personalized medicine in Latin America, located in Monterrey city, Nuevo León, México. Vitagénesis’ mission is to advance research and development that translates into diagnostic and therapeutic innovations.
Vitagénesis is a research center that develops and offers services in cell biology and genomics. The company was created by the Business Incubation and Technology Transfer Center of the Autónoma University of Nuevo León, seeking to capitalize on the expertise of its founding team in Molecular Biology and Genomics. Vitagénesis has exceptional human capital, cutting-edge experimental infrastructure and strategic alliances in the Life Sciences sector.
Through this exclusive agreement, THB aims to provide the Mexican Academic Community of Biobanks, in particular, those specialized in Infectious Diseases and Oncology, with the operational framework support needed to promote their deserved international visibility.
“After I started the National Biobank Laboratory in Mexico and introduced good biobanking practices in the associated institutions, two main challenges still remain to be solved: becoming sustainable and gaining recognition from international pharma and diagnostic companies as reliable and expert sources of high quality biospecimens to support their biomarker R&D programs.”
“This is why not only are we very honoured that THB has signed this partnership agreement, but we are also convinced that THB’s expertise and reputation will definitely help put the Mexican biobank community on the map.” – Professor Hugo A. Barrera-Saldaña, Founder and General Director of Vitagénesis
“Prof. Barrera and his collaborators are not only leaders and very knowledgeable in biobanking but have also championed in biomedical translational research. This partnership strengthens THB’s presence internationally and is a valuable addition to our existing worldwide network of partnered academic biobanks.”
“It constitutes for us an important first step in our expansion in Latin America, whose great biobanking capabilities to date have been underestimated and underutilized by Industry even though pathology labs, clinical sites and CRO laboratory platforms provide an excellent scientific expertise, high quality standards and compliance with regulatory and ethical requirements” – Dr. Pascal Puchois, Chief Executive Officer at THB.
Sources:
